期刊文献+

晚期肺腺癌治疗方法 被引量:5

A systematic review of treatment strategies for advanced lung adenocarcinoma
原文传递
导出
摘要 肺腺癌是肺癌的常见类型,但多数确诊时已属晚期。虽然目前无法治愈,但随着研究的不断深入、技术的不断完善,针对晚期肺腺癌的治疗方法如化疗、分子靶向治疗、化疗与靶向药物间插联合疗法、免疫治疗等正逐渐趋于精准化、个体化,使患者生存时间延长、生活质量提高。本文就现行的治疗方法作简要综述。 Lung adenocarcinoma is the most common pathological type of lung cancer,but in most cases it has already locally advanced or distantly metastasized when diagnosed. It can't be cured at present, but with the development of the research and technology, many treatment methods for advanced lung adenocarcinoma will be gradually accurate and individual, for example, chemotherapy, molecular targeted therapy,intercalated combination therapy,immunotherapy and so on. These therapeutic regimens bring about substantial prolongation of survival life and improvement in life quality for those advanced lung adenocarcinoma patients. In this article, we will make a brief review for the current treatment strategies.
作者 张岩 刘瑞娟
出处 《国际呼吸杂志》 2015年第22期1734-1738,共5页 International Journal of Respiration
关键词 晚期肺腺癌 化疗 分子靶向治疗 间插联合疗法 免疫治疗 个体化 Advanced lung adenocarcinoma Chemotherapy Molecular targeted therapy Intercalated combination therapy Immunotherapy Individual
  • 相关文献

参考文献38

  • 1Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis [J]. JAMA,2004,292(4) :470-484.
  • 2D'addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non- small-cell lung cancer: a meta-analysis of the published literature[J]. J Clin Oncol, 2005,23 (13) : 2926-2936.
  • 3Seagliotti GV,Parikh P, Von Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced- stage non-small-cell lung cancer[J]. J Clin Oncol, 2008, 26 (21) :3543-3551.
  • 4Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase Ⅲ trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) : P2-328[J]. J Thorae Oncol, 2007,2(8) :S851.
  • 5Fidias PM, Dakhil SR, Lyss AP, et al. Phase Ⅲ study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine pluscarboplatin in advanced non- small-cell lung cancer[J]. J Clin Oncol, 2009,27 (4) :591-598.
  • 6Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non- small cell lung cancer[J]. Br J Cancer, 2011,104 (10) : 1594- 1601.
  • 7Ahn M,Sun J,Ahn JS,et al. Cisplatin plus pemetrexed (CP) versus cisplatin plus gemeitabine ( CG ) according to thymidylate synthase expression in non-squamous NSCLC: A biomarker-stratified randomized phase Ⅱ trial [ C]. 2014 ESMO Congress : Abstract LBA42.
  • 8Shepherd FA, Douillard J, Fukuoka M, et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC) :Meta-analysis from four clinical trials[J]. J Clin Oncol, 2009,27 (Suppl) : abstr 8011.
  • 9Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small- cell lung cancer:current knowledge and future directions[J]. J Clin Oncol, 2005,23(11) : 2556-2568.
  • 10Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med,2009,361(10) :947-957.

同被引文献46

引证文献5

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部